# Systemic Therapy Update

Volume 4, Number 9

for health professionals who care for cancer patients
Available on website www.bccancer.com

October 2001

#### INSIDE THIS ISSUE

- Benefit Drug List Trastuzumab in Combination with Vinorelbine
- Protocol Update BRAVTRNAV, CNCCNU, CNMODPCV, CNTEMOZ, SCHYPCAL
- Cancer Management Manual Breast Tumour, Guidelines for the Care of Radiation Skin Reaction, Guidelines for the Care of Chronic Ulcerating Malignant Skin Lesions
- Pre-Printed Order Update BRAVCLOD, BRAVPAM, UBRAJACT, CNTAMCAR, GIGAI, GIRLAIFF, UGUGEMCIS, GUPMX, LYRITUX
- Patient Education New Drug Information Handouts, Dyspnea Patient Education Pamphlet
- Drug Update Bleomycin, Irinotecan and GIIRFUFA Protocol
- Cancer Drug Manual New Drug Monographs and Patient Information
- Supportive Care Dyspnea Patient Education Pamphlet
- Provincial Systemic Therapy Program Policies
- Library/Cancer Information Centre
- Continuing Education BC Cancer Agency Annual Cancer Conference
- Erratum BRAVDOC

FAX request form and IN TOUCH phone list are provided if additional information is needed.

#### **BENEFIT DRUG LIST**

The following new program has been funded by the Provincial Systemic Therapy Program effective:

 Trastuzumab in combination with vinorelbine for breast cancer

This new indication is now added to the existing Class II drug on the benefit list. A Class II form

must be completed and submitted to the Provincial Systemic Therapy Program before the drug will be dispensed at a regional cancer centre or reimbursed to a community hospital.

Susan O'Reilly, MB, FRCPC Provincial Systemic Program Leader

The current Benefit Drug List and Class II forms are available on the website www.bccancer.bc.ca.

#### PROTOCOL UPDATE

**Protocols by Drugs Index** A cross-referenced index has been created which lists the BC Cancer Agency benefit drugs with their corresponding protocols. This index can be obtained via H-drive at regional cancer centres or Fax-back as listed at the end of the Update.

Protocol codes for treatments requiring "Undesignated Indication" approval prior to use are prefixed with the letter  $\boldsymbol{U}$ .

- INDEX to BC Cancer Agency Protocol Summaries revised monthly (includes tumour group, protocol code, indication, drugs, last revision date and version)
- BRAVTRNAV new: Palliative therapy for metastatic breast cancer using trastuzumab (Herceptin®) and vinorelbine
- CNCCNU revised (new indications added, reformatted): Lomustine (CCNU) for first line treatment of recurrent malignant brain tumors
- CNMODPCV revised (new indications added, dose modifications clarified, reformatted): Modified PCV adjuvant chemotherapy grade III astrocytoma
- CNTEMOZ revised (new indications added, reformatted): Second line therapy for recurrent malignant gliomas using temozolomide

■ SCHYPCAL revised (cost of pamidronate dose): Guidelines for the diagnosis and management of malignancy related hypercalcemia

Most protocols are available on the BC Cancer Agency website <a href="https://www.bccancer.bc.ca">www.bccancer.bc.ca</a>.

#### **CANCER MANAGEMENT MANUAL**

**Breast Tumour** section has been revised.

Guidelines for the Care of Radiation Skin Reactions is a new section added to the Manual.

Guidelines for the Care of Chronic Ulcerating Malignant Skin Lesions is a new section added to the Manual.

The Cancer Management Manual is available on BC Cancer Agency website <a href="https://www.bccancer.bc.ca">www.bccancer.bc.ca</a>.

#### PRE-PRINTED ORDER UPDATE

Pre-printed orders should always be checked with the most current BC Cancer Agency protocol summaries. The Vancouver Cancer Centre has prepared the following chemotherapy pre-printed orders, which can be used as a guide for reference:

- **BRAVCLOD** (pre-printed order entitled BRCLODIV) revised (labs and clodronate infusion time): Therapy for bone metastases in breast cancer using clodronate
- BRAVPAM (pre-printed order entitled BRCLODIV) revised (labs and clodronate infusion time): Therapy for bone metastases in breast cancer using clodronate
- **UBRAJACT** (pre-printed order entitled BRAVTAX) revised (Class II eligibility, labs and appointments): Adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel
- CNTAMCAR new: In-house phase II pilot study utilizing carboplatin and high dose tamoxifen
- **GIGAI** new: Combined modality adjuvant therapy for completely resected gastric adenocarcinoma using fluorouracil + folinic acid (leucovorin) + radiation therapy
- **GIRLAIFF** revised: Preoperative concurrent chemotherapy and radiotherapy and

- postoperative chemotherapy for locallyadvanced (borderline resectable or unresectable) rectal adenocarcinoma
- UGUGEMCIS new: Palliative therapy for urothelial carcinoma using cisplatin and gemcitabine
- GUPMX new: Palliative therapy for hormonerefractory prostate cancer using mitoxantrone and prednisone
- LYRITUX revised (dilution volume):
   Treatment of lymphoma with single agent rituximab

An index to the orders can be obtained by Fax-back.

#### **PATIENT EDUCATION**

**New Drug Information Handouts** for a number of drugs have been developed or completely revised. Please see under <u>Cancer Drug Manual</u> for more details.

**Dyspnea patient education pamphlet** see under <u>Supportive Care</u>.

Patient handouts on cancer drugs are available on the H-drive (h:\everyone\systemic\chemo\pt educ\) and our website. Copies of these handouts are also available via Fax-back.

#### **DRUG UPDATE**

Bleomycin Associated Lung Toxicity A guideline for oxygen therapy for patients who have received bleomycin has been developed by the BC Cancer Agency GU Tumour Group and Provincial Systemic Therapy Program. It provides recommendations for oxygen therapy based on available evidence relating bleomycin pulmonary toxicity to supplemental oxygen therapy. This information has been incorporated into the Bleomycin drug monograph of the Cancer Drug Manual on our website.

Irinotecan Safety Information Letter for patients starting GIIRFUFA The BC Cancer Agency GI Systemic Therapy Working Group and the Provincial Systemic Therapy Program have recommended that all new patients receiving GIIRFUFA be given an additional "Irinotecan GIIRFUFA Letter" along with the usual package of

irinotecan, fluorouracil and leucovorin patient handouts. This letter was issued by Pharmacia, the manufacturer of irinotecan, at the request of Health Canada in response to preliminary safety information related to this treatment regimen from two ongoing clinical trials. This new policy is effective as of 17 September. Copies of the letter can be obtained from the H-drive (h:\everyone\systemic\chemo\pt educ\Irinotecan GIIRFUFA letter.doc), Fax-back or our website irinotecan patient information handout.

#### **CANCER DRUG MANUAL**

New Drug Monographs and Patient Information As part of the ongoing revision for the Cancer Drug Manual third edition project, the following monographs and patient information handouts have been completely revised or developed:

1.	Anastrozole	11. Octreotide	
2.	Bicalutamide	12. Oxaliplatin	
3.	Capecitabine	13. Pamidronate	
4.	Carboplatin	14. Raltitrexed	
5.	Clodronate	15. Rituximab	
6.	Docetaxel	16. Temozolomide	
7.	Exemestane	17. Topotecan	
8.	Gemcitabine	18. Trastuzumab	
9.	Irinotecan	19. Tretinoin	
10. Letrozole		20. Vinorelbine	

Copies of these monographs and patient information have been sent out to all Communities Oncology Network hospitals. They are also available via our <a href="website">website</a> and the H-drive (h:\everyone\systemic\chemo\cancer drug manual monographs).

The Cancer Drug Manual is available on the BC Cancer Agency website <a href="https://www.bccancer.bc.ca">www.bccancer.bc.ca</a>.

#### **SUPPORTIVE CARE**

**Dyspnea patient education pamphlet** has been developed by the Pain and Symptom Management/Palliative Care Program. Copies are available from the BC Cancer Agency Library/Cancer Information Centre.

### PROVINCIAL SYSTEMIC THERAPY PROGRAM POLICIES

BC Cancer Agency Systemic Therapy Policies are available at <a href="https://hittps:

#### **LIBRARY/CANCER INFORMATION CENTRE**

Unconventional Cancer Therapies Manual is available on the BC Cancer Agency website at <a href="https://www.bccancer.bc.ca">www.bccancer.bc.ca</a>. The manual consists of 46 short monographs on the more commonly used unconventional cancer therapies (e.g., Essiac, vitamins, teas, shark cartilage) and includes tips for the patient and family on how unconventional therapies can be evaluated. For each therapy the manual provides proponent/advocate claims, as well as by evidence-based evaluation/critique quotations from the literature.

#### **CONTINUING EDUCATION**

**BCCA Annual Cancer Conference** will be held at the Wall Centre, Vancouver, on 22-24 November 2001. The conference will include presentations for physicians, nurses, patient and family counsellors, pharmacists. For more details, please contact Jack Chritchley at (604) 877 6183.

#### **ERRATUM**

**Protocol Update of BRAVDOC** in the July 2001 issue has read as follows:

BRAVDOC revised (eligibility): Palliative therapy for metastatic breast cancer using docetaxel (not doxorubicin and cyclophosphamide

Mário de Lemos, PharmD (Editor)

Sharon Allan, MD Sandi Broughton, BA (Econ), MSc Jack Chritchley, MD Karen Janes, MSN David Noble, BSc, BLS Jaya Venkatesh, BCom, BA, MHA Susan Walisser, BSc (Pharm)

Gigi Concon (Secretary)

In Touch	www.bccancer.bc.ca	bulletin@bccancer.bc.ca
BC Cancer Agency	(604)-877-6000	Toll-Free 1-(800)-663-3333
Communities Oncology Network	Ext 2744	jchritch@bccancer.bc.ca
Nursing Professional Practice	Ext 2623	ilundie@bccancer.bc.ca
Pharmacy Professional Practice	Ext 2247	gconcon@bccancer.bc.ca
Provincial Systemic Therapy Program	Ext 2247	gconcon@bccancer.bc.ca
Communities Oncology Network Pharmacist	Ext 2515	francish@bccancer.bc.ca
Drug Information	Ext 3028	robrien@bccancer.bc.ca
Library / Cancer Information	Ext 2690	dnoble@bccancer.bc.ca
Update Editor	Ext 2288	mdelemos@bccancer.bc.ca
Cancer Centre for the Southern Interior (CCSI)	(250) 712-3900	Toll-Free 1-(888)-563-7773
Fraser Valley Cancer Centre (FVCC)	(604)-930-2098	Toll-Free 1-(800)-523-2885
Vancouver Cancer Centre (VCC)	(604)-877-6000	Toll-Free 1-(800)-663-3333
Vancouver Island Cancer Centre (VICC)	(250) 519-5500	Toll-Free 1-(800)-670-3322

#### **REGIONAL CANCER CENTRE ACCESS**

BULLETIN UPDATES	LOCATION	
Patient Handouts:	H:\everyone\systemic\chemo\Pt Ed	uc_
Anagrelide	BRAVTAM	Octreotide
Anastrozole	<u>Cabergoline</u>	<u>Oxaliplatin</u>
<u>Bicalutamide</u>	<u>Capecitabine</u>	<u>Pamidronate</u>
BRAJAC	<u>Carboplatin</u>	<u>Raltitrexed</u>
BRAJCAF	Clodronate IV/Clodronate PO	<u>Rituximab</u>
<u>BRAJCEF</u>	<u>Docetaxel</u>	<u>Temozolomide</u>
<u>BRAJCMF</u>	<u>Exemestane</u>	<u>Thalidomide</u>
<u>BRAJCMFPO</u>	<u>Gemcitabine</u>	<u>Topotecan</u>
<u>BRAJTAM</u>	<u>Irinotecan</u>	<u>Trastuzumab</u>
<u>BRAVCAF</u>	Irinotecan GIIRFUFA Letter	<u>Tretinoin</u>
<u>BRAVCMF</u>	<u>Letrozole</u>	<u>Vinorelbine</u>
Pre-Printed Orders	H:\everyone\systemic\chemo\Orders	s <u>\VCC</u>
Index of Pre-Printed Orders		<u>Index.doc</u>
BRAVCLOD IV/ BRAVCLOD PO	<u>CNTAMCAR</u>	<u>UGUGEMCIS</u>
<u>BRAVPAM</u>	GIGAI	<u>GUPMX</u>
<u>UBRAJACT</u>	GIRLAIFF	<u>LYRITUX</u>
Protocol Summaries	<u>H:\everyone\systemic\chemo\Protocol\"tumour site"</u>	
Index of Protocol Summaries		<u>Index_NT</u> or <u>Index_W6</u>
Index of Protocols by Drugs	<u>BRAVTRNAV</u>	<u>CNTEMOZ</u>
	<u>CNCCNU</u>	<u>SCHYPCAL</u>
	<u>CNMODPCV</u>	
Reimbursement	H:\everyone\systemic\chemo\Reimburs	
Benefit Drug List (1 October 2001)	<u>BenefitList.doc</u>	
Class 2 Form (1 October 2001)	<u>Class2.doc</u>	
Filgrastim Usage Form (1 June 2001)	GCSF form orig.doc	
Systemic Therapy Update Index	H:\everyone\systemic\chemo\Update	

For easy access, double-click your systemic chemo icon. We appreciate your comments. Write us at <a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>

#### BC CANCER AGENCY SYSTEMIC THERAPY UPDATE FAX REQUEST FORM

FAX (604) 877-0585

bulletin@bccancer.bc.ca

TO SUBSCRIBE: FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247

## FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247 OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247 PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES

I WOULD PREFER TO RECEIVE THIS INFORMATION VIA: ☐ E-mail (Word 6.0) (a) ☐ Fax ( ) Attn: **UPDATES** Please **☑** Fax-Back information below: All items Patient Handouts: (also available on our website www.bccancer.bc.ca) Anagrelide BRAVTAM Octreotide Anastrozole Cabergoline Oxaliplatin Pamidronate Bicalutamide Capecitabine BRAJAC Carboplatin Raltitrexed **BRAJCAF** Clodronate Rituximab **BRAJCEF** Docetaxel (Taxotere) Temozolomide **BRAJCMF** Exemestane Thalidomide BRAJCMFPO Gemcitabine Topotecan **BRAJTAM** Irinotecan Trastuzumab (Herceptin) **BRAVCAF** Irinotecan GIIRFUFA letter Tretinoin **BRAVCMF** Letrozole Vinorelbine Pre-Printed Orders: **BRAVCLOD GIGAI** GIRLAIFF **BRAVPAM UBRAJACT UGUGEMCIS CNTAMCAR GUPMX** Index: Pre-Printed Orders LYRITUX Protocol Summaries: (also available on our website www.bccancer.bc.ca) **BRAVTRNAV** CNTEMOZ CNCCNU SCHYPCAL **CNMODPCV** Index: Protocol Summaries (current month) Index: Protocols by Drugs Index Reimbursement (also available on our website www.bccancer.bc.ca) Benefit Drug List (01 October 2001) Class 2 Form (01 October 2001) Filgrastim Usage Form (01 June 2001) Systemic Therapy Update Index (also available on our website www.bccancer.bc.ca) Jan-Dec 2000

Jan-Jun 2001